Apcegen Technologies Secures NSTEDB and TePP Funding's from DST

Printer-friendly versionPDF version

Apcegen Technologies, a start-up Biopharma development company has announced today that Apcegen has secured seed support under NSTEDB and TePP schemes from Department of Science and Technology (DST) for the development of two of it's Biobetters.

Bengaluru, Karnataka, February 18, 2013 - (PressReleasePoint) - Apcegen is fully integrated Innovation driven Biopharmaceutical company, nurtured by a group of highly trained and qualified technocrats and supported by IIT Kanpur. Apcegen started its operations in March 2011 at Indian Institute of Technology (IIT) Kanpur, INDIA. Apcegen aims to discover, develop and manufacture human therapeutics with blend of advances in molecular biology & cell engineering with focus on combat diseases like Inflammation and Oncology. Apcegen commits in helping millions of human beings around the world in the fight against cancer, rheumatoid arthritis, and other life threatening diseases.

The group focuses on pathway engineering and development of novel expression systems, and generation of over-expressing stable cell lines, development of proprietary expression platforms and novel, scalable processes in both microbial and mammalian systems Apcegen, in association with institutes of repute is also working on the development of novel and cost effective platforms. Apcegen Technologies will use its skills to make affordable biotechnology based healthcare solutions through cGMP compliant fast track development of bioprocesses for the development of cutting edge biotherapeutic products. The unique expertise available with Apcegen Technologies for developing cost effective and efficient bioprocesses will enable rapid and efficient commercialization of affordable, high quality recombinant biotherapeutics.

So far Apcegen has developed a recombinant clone expressing a fusion protein targeted against various forms of Arthritis and is aggressively working onto develop two first in class biobetters against RA and breast cancer.